Get the Stockscreener App
1.13
1.74%
-0.02
Lineage Cell Therapeutics Inc stock is traded at $1.13, with a volume of 1.67M.
It is down -1.74% in the last 24 hours and up +5.61% over the past month.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
See More
Previous Close:
$1.15
Open:
$1.16
24h Volume:
1.67M
Relative Volume:
0.76
Market Cap:
$258.04M
Revenue:
$8.95M
Net Income/Loss:
$-21.49M
P/E Ratio:
-9.4167
EPS:
-0.12
Net Cash Flow:
$-29.24M
1W Performance:
+17.60%
1M Performance:
+5.61%
6M Performance:
+77.67%
1Y Performance:
+8.65%
1-Day Range:
$1.12
$1.21
1-Week Range:
$0.9296
$1.21
52-Week Range:
$0.3651
$1.21
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Name
Lineage Cell Therapeutics Inc
Sector
Industry
Phone
510-871-4188
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.13 | 262.61M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Initiated | Craig Hallum | Buy |
| Nov-02-22 | Initiated | Robert W. Baird | Outperform |
| Jun-14-22 | Initiated | B. Riley Securities | Buy |
| Aug-19-21 | Initiated | Noble Capital Markets | Outperform |
| Mar-31-21 | Initiated | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Stock (LCTX) Latest News
Detecting support and resistance levels for Lineage Cell Therapeutics Inc. AI Short-Term Gain Forecast with Data - Newser
Using AI based signals to follow Lineage Cell Therapeutics Inc. High Accuracy Trade Setup Identification - Newser
How does Lineage Cell Therapeutics Inc. generate profit in a changing economyCapitalize on market momentum for maximum gains - jammulinksnews.com
When is Lineage Cell Therapeutics Inc. stock expected to show significant growthBuild wealth steadily with proven stock picks - jammulinksnews.com
Published on: 2025-07-28 09:01:19 - jammulinksnews.com
How does Lineage Cell Therapeutics Inc. compare to its industry peersUnlock steady growth with low-risk stocks - jammulinksnews.com
Published on: 2025-07-28 01:44:51 - jammulinksnews.com
Does Lineage Cell Therapeutics Inc. stock perform well during market downturnsStay ahead with daily market updates - jammulinksnews.com
Is Lineage Cell Therapeutics Inc. a good long term investmentFree Smart Trading Workshop - PrintWeekIndia
Lineage Cell Therapeutics Inc. Stock Analysis and ForecastTremendous growth opportunities - PrintWeekIndia
What analysts say about Lineage Cell Therapeutics Inc. stockPhenomenal investment performance - PrintWeekIndia
What drives Lineage Cell Therapeutics Inc. stock priceFree Consultation - PrintWeekIndia
Stem Cell Therapy Market Attracts Investment in Neuro, Onco & - openPR.com
Why Lineage Cell Therapeutics Inc. stock attracts strong analyst attentionHigh Return Conservative Stocks - Newser
What makes Lineage Cell Therapeutics Inc. stock price move sharplyFree Stock Market Practical Discussion Forums - Newser
How Lineage Cell Therapeutics Inc. stock performs during market volatilityBreakout Momentum Stocks - Newser
Spinal Cord Injury Pipeline 2025: MOA And ROA Insights, Clinical Trials Status, And Key Companies Involved By Delveinsight Stemcyte, Nervgen Pharma, VA Office Of Research And Development, Kessler - MenaFN
Cell Therapy Manufacturing Market Exclusive Report with - openPR.com
Cell Therapy Manufacturing Market In-depth Insights, Business - openPR.com
Lineage Cell Therapeutics shareholders approve board slate and equity plan amendment - Investing.com
Lineage Cell stock holds steady as Roche presents positive 3-year data By Investing.com - Investing.com South Africa
Lineage Cell Therapeutics (LCTX) Drops 1.65% Amid OpRegen Trial Hype - AInvest
Two Sigma Investments LP Buys New Shares in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Inc Stock (LCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):